Skip to main content

Table 4 Cardiovascular benefits of GLP-1 agonists

From: Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

Trial Agents MACEs (HR/p) CV death (HR/p) HF (HR/p) Renal outcome (HR/P)
ELIXA Lixisenatide 1.02/0.78 0.98/0.85 0.96/0.75 0.84/0.083
LEADER3 Liraglutide 0.87/0.01 0.98/0.85 0.87/0.14 0.78/0.003
SUSTAIN-6 Semaglutide 0.74/0.016 0.98/0.92 1.11/0.57 0.64/0.005
EXSCEL Exenatide 0.91/0.061 0.88/0.096 0.94/0.49 0.88/0.065
REWIND Dulaglutide 0.88/0.026 0.91/0.21 0.93/0.46 0.85/0.0004
HARMONY Albiglutide 0.78/0.0006 0.93/0.58 0.71/0.019 #
AMPLITUDE-O Efpeglenatide 0.73/0.0069 0.72/0.07 0.61/0.04 0.68/ < 0.0001
  1. p p values, # missing data, MACE major adverse cardiac events, HR hazard ratio, CV cardiovascular, HF heart failure